Diabetic kidney disease: act now or pay later

Journal of the American Society of Hypertension

Volumn 4, Issue 1, 2010, Pages 3-6

  Atkins, Robert C ^a   Zimmet, Paul ^b  

^a Society of Nephrology/International Federation of Kidney Foundations   (Australia)

^b International Diabetes Federation ^*

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

BLOOD PRESSURE REGULATION; COMPUTER PROGRAM; DEVELOPING COUNTRY; DIABETIC NEPHROPATHY; DIALYSIS; EARLY DIAGNOSIS; EARLY INTERVENTION; EDITORIAL; GLYCEMIC CONTROL; HEALTH CARE COST; HEALTH PROGRAM; HEALTH PROMOTION; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INFORMATION STORAGE; KIDNEY FAILURE; LIFESTYLE MODIFICATION; MASS SCREENING; NATIONAL HEALTH ORGANIZATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; PREVENTIVE HEALTH SERVICE; PRIMARY PREVENTION; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; RISK ASSESSMENT; WEB BROWSER;

DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE MANAGEMENT; HEALTH EDUCATION; HUMANS; MASS SCREENING; RESEARCH; WORLD HEALTH;

EID: 77949320534     PISSN: 19331711     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jash.2009.12.001     Document Type: Editorial

References (28)

1. Diabetes and kidney disease: time to act (2003), International Diabetes Federation and International Society of Nephrology, Brussels, Belgium
2. Zimmet P., Alberti K., and Shaw J. Global and societal implications of the diabetes epidemic. Nature 414 (2001) 782-787
3. King H., Aubert R., and Herman W. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 21 (1998) 1414-1431
4. Yoon K., Lee J.H., Kim J.W., et al. Epidemic obesity and type 2 diabetes in Asia. Lancet 368 (2006) 1681-1688
5. Sicree R., Shaw J., and Zimmet P. Diabetes and impaired glucose tolerance. In: Gan D. (Ed). Diabetes Atlas. 3rd edn (2006), International Diabetes Federation, Brussels 15-109
6. Reutens A.T., Prentice L., and Atkins R. The epidemiology of diabetic kidney disease. In: Ekoé J.-M., Rewers M., Williams R., and Zimmet P. (Eds). The Epidemiology of Diabetes Mellitus. 2nd edn (2008), John Wiley & Sons, Chichester 499-518
7. International comparisons. United States Renal Data System. 2007 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States (2007), National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland, USA 239-254
8. Appendix II. In: McDonald S., Excell L., and Livingston B. (Eds). ANZDATA Registry Report 2008 (2008), Australia and New Zealand Dialysis and Transplant Registry, Adelaide 1-97
9. Yamagata K., Iseki K., Nitta K., et al. Chronic kidney disease perspectives in Japan and the importance of urinalysis screening. Clin Exp Nephrol 12 (2008) 1-8
10. Lysaght M. Maintenance dialysis population dynamics: current trends and long-term implications. J Am Soc Nephrol 13 (2002) S37-S40
11. Adler A.I., Stevens R.J., Manley S.E., et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 63 (2003) 225-232
12. Retnakaran R., Cull C.A., Thorne K.I., et al. Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74. Diabetes 55 (2006) 1832-1839
13. Parving H.-H., Lewis J.B., Ravid M., et al. Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective. Kidney Int 69 (2006) 2057-2063
14. Ninomiya T., Perkovic V., de Galan B.E., et al. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol 20 (2009) 1813-1821
15. Dunstan D.W., Zimmet P.Z., Welborn T.A., et al. The rising prevalence of diabetes and impaired glucose tolerance: the Australian Diabetes, Obesity and Lifestyle Study. Diabetes Care 25 (2002) 829-834
16. White S.L., Polkinghorne K.R., Cass A., et al. Limited knowledge of kidney disease in a survey of AusDiab study participants. Med J Aust 188 (2008) 204-208
17. Whaley-Connell A., Sowers J.R., McCullough P.A., et al. Diabetes mellitus and CKD awareness: the Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES). Am J Kidney Dis 53 Suppl 4 (2009) S11-S21
18. Thomas M., Viberti G., and Groop P. Screening for chronic kidney disease in patients with diabetes: are we missing the point?. Nat Clin Pract Nephrol 4 (2008) 2-3
19. Holman R.R., Paul S.K., Bethel M.A., et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359 (2008) 1577-1589
20. Bilous R. Microvascular disease: what does the UKPDS tell us about diabetic nephropathy?. Diabet Med 25 Suppl 2 (2008) 25-29
21. Gaede P., Lund-Andersen H., Parving H.-H., et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 358 (2008) 580-591
22. Patel A., and and ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 370 (2007) 829-840
23. ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358 (2008) 2560-2572
24. Zoungas S., de Galan B.E., Ninomiya T., et al. Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: new results from the ADVANCE trial. Diabetes Care 32 (2009) 2068-2074
25. Ruggenenti P., Fassi A., Ilieva A.P., et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 351 (2004) 1941-1951
26. Parving H.-H., Lehnert H., Brochner-Mortensen J., et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345 (2001) 870-878
27. Lewis E.J., Hunsicker L.G., Clarke W.R., et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345 (2001) 851-860
28. Burney B., Kalaitzidis R., and Bakris G. Novel therapies of diabetic nephropathy. Curr Opin Nephrol Hypertens 18 (2009) 107-111